Bod Science Limited

BOD

AU0000181331

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 23:59:52 2023-11-22 EST			5-day change	1st Jan Change
0.024 ^AUD	-7.69%		-.--%	-.--%

05-29	Bod Science Announces Delay of Half-Year Report Lodgment	MT
03-25	Bod Science Announces Delay in Appendix 4D Lodgement	MT

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2021

August 20, 2020 at 07:02 pm

Bod Australia Limited provided revenue guidance for the fiscal year 2021. The company expects that revenue will further increase during fiscal year 2021, driven by recurring sales orders, new product launches and international expansion.

Latest news about Bod Science Limited

Bod Science Announces Delay of Half-Year Report Lodgment	05-29	MT
Bod Science Announces Delay in Appendix 4D Lodgement	03-25	MT
BOD Science Signs Supply Agreement in Medicinal Cannabis with Green Farmers	12-13	MT
Bod Science Limited Enters into Supply Agreement with Green Farmers	12-12	CI
Bod Science Receives AU$1.6 Million R&D Tax Refund; Shares Rise 8%	11-21	MT
Bod Expects to Receive Funds from Antah Soon	11-21	MT
Bod Science Delays Settlement of Tranche 1 of AU$2.1 Million Placement	11-16	MT
Bod Science Raises AU$2.1 Million Via Share Placement; Shares Fall 43%	11-07	MT
Bod Science Limited announced that it expects to receive AUD 2.05 million in funding	11-07	CI
Australian Shares Retreat as Monthly CPI Indicator Rises	23-09-27	MT
Bod Science Validates Greater Bioavailability of Drug Delivery Technology; Shares Rally 12%	23-09-26	MT
Bod Science Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Bod Science Limited Announces Change of Principal Place of Business	23-08-14	CI
Bod Science Completes Acquisition of Drug Delivery Technology; Shares Up 3%	23-08-10	MT
Bod Australia Limited completed the acquisition of Aqua Phase Ltd.	23-08-09	CI
Bod Science Validates Bioavailability of Aqua Phase Technology	23-07-25	MT
Bod Science Signs Letter of Intent to Sell Medical Cannabis Products in Malaysia	23-06-21	MT
US Debt Ceiling Caution Dampens Appetite for Australian Equities	23-05-23	MT
Bod Australia Secures Ethics Approval for Drug Delivery Study; Shares Jump 10%	23-05-23	MT
Bod Science Limited Announces David Baker Assumes an Additional Advisory Role to Support Management to Progress A Number of Commercial Initiatives	23-04-23	CI
BOD Science Completes Recruiting for Phase IIb Clinical Trial of CBD Product	23-04-03	MT
Bod Science Limited Announces Pharmacokinetic Study to Confirm the Bioavailability of Aqua Phase Submitted for Ethics Approval	23-03-27	CI
Bod Science Completes Screening for Phase 2 Insomnia Trial	23-03-13	MT
Bod Science Limited Provides the Update on Their Phase IIB Clinical trial	23-03-12	CI
Bod Science Limited Updates on Acquisition of Aqua Phase Technology	23-03-06	CI

Chart Bod Science Limited

Duration

Period

More charts

Company Profile

Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for consumer and medical markets. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Companyâs segments include medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q4 2024 Earnings Release (Projected)

More about the company